Maxcyte (MXCT) Other Operating Expenses (2020 - 2026)

Maxcyte (MXCT) has 7 years of Other Operating Expenses data on file, last reported at $3.4 million in Q1 2026.

• Quarterly Other Operating Expenses rose 131.26% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$31.0 million (up 34.81% YoY) and the FY2025 annual result came in at -$46.5 million, up 2.61% from the prior year.
• Other Operating Expenses rose to $3.4 million in Q1 2026 per MXCT's latest filing, from -$9.6 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $8.3 million in Q4 2023 and bottomed at -$13.2 million in Q3 2024.
• The 5-year median for Other Operating Expenses is $3.4 million (2026), against an average of -$2.2 million.
• The widest annual swing landed in 2024, when Other Operating Expenses slumped 263.61%; it then jumped 131.26% in 2026.
• Tracing MXCT's Other Operating Expenses over 5 years: stood at $6.3 million in 2022, then jumped by 32.15% to $8.3 million in 2023, then tumbled by 248.56% to -$12.3 million in 2024, then gained by 21.8% to -$9.6 million in 2025, then soared by 135.58% to $3.4 million in 2026.
• Per Business Quant, the three latest MXCT Other Operating Expenses figures stand at $3.4 million (Q1 2026), -$9.6 million (Q4 2025), and -$12.4 million (Q3 2025).

Peer Comparison